Shorts say: The European commercial launch of Esbriet is still a slow work in progress. Competition could negatively impact InterMune next year when Boehringer Ingelheim is expected to announce results from phase III studies of nintedanib. Then there's the uncertainty surrounding InterMune's own U.S.-based phase III study of Esbriet -- results are also expected next year. 9. Hyperion Therapeutics (HPTX) Short interest: 26% of float ^NBI data by YCharts
Shorts say: Can Hyperion really get away with charging $295,000 per year for Ravicti as a therapy for urea cycle disorders, even if it's more convenient than the less expensive alternative, Buphenyl? 8. Arena Pharmaceuticals (ARNA - Get Report) Short interest: 26.5% of float ^NBI data by YCharts
Shorts say: Belviq is a weak weight-loss drug. The commercial launch will be disappointing.